EBC is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners.
24 03-2025

EBC’s statement on the public consultation regarding rare diseases by the European Parliament’s Committee on Public Health

2025-03-25T08:47:36+00:0024-03-2025|News|

On February 28, marking the 2025  Rare Disease Day, the European Parliament’s Public Health Committee (SANT) kicked off its survey on rare diseases.  The purpose of this public consultation is to provide a basis for the forthcoming work of the Committee in bringing a better understanding of the challenges of persons affected by rare diseases and views of [...]

21 03-2025

EBC Launches ‘Rethinking Schizophrenia: Optimising the Schizophrenia Care Pathway’ 

2025-03-27T09:20:43+00:0021-03-2025|News|

EBC is thrilled to launch the Research Paper resulting from the second phase of the Rethinking Schizophrenia project, which focused on optimising the care pathway. This report, a collaborative effort from the European Brain Council (EBC) and the European Psychiatric Association (EPA), builds directly on the previous 'Beyond the Voices' Policy Report released in [...]

17 03-2025

EBC Launches ‘Rethinking Myasthenia Gravis’ to Propose Policy Recommendations for an Improved Care Pathway

2025-03-17T13:07:57+00:0017-03-2025|News|

The European Brain Council (EBC), in collaboration with the Institute of Management of Scuola Superiore de Sant'Anna, was very pleased to launch the 'Rethinking Myasthenia Gravis' project on the occasion of EBC's Rare Disease Day event, held on February 20th in Brussels. Rethinking Myasthenia Gravis (MG) is a research-driven project that will offer policy [...]

13 03-2025

Rethinking Schizophrenia Policy Recommendations Call for Change in Schizophrenia Care Pathways

2025-03-13T11:35:45+00:0013-03-2025|News|

As a first glimpse into the second phase of the “Rethinking Schizophrenia’ project, this brief policy report provides an introduction to the ‘Optimising the Schizophrenia Care Pathway’ project, as well as the resulting policy recommendations. This report, a collaborative effort from the European Brain Council (EBC) and the European Psychiatric Association (EPA), builds directly [...]

6 03-2025

EBC endorses ‘Science Matters!” Statement by Federation of European Neuroscience Societies (FENS)

2025-03-06T08:58:26+00:0006-03-2025|News|

The European Brain Council is pleased to endorse "Science Matters!", a statement from FENS – the Federation of European Neuroscience Societies & Allies. Science drives discoveries that expand knowledge and understanding of ourselves, the world, and future possibilities, based on rigorous, evidence-based research. Together with many others, FENS – the Federation of European Neuroscience [...]

5 03-2025

New Report Reveals – Everyone Benefits from Less Alcohol

2025-03-06T11:57:45+00:0005-03-2025|News|

Reducing alcohol consumption improves both individual and societal health – this is the key finding of a new research review presented on Wednesday 5 March 2025  during the launch event "Health & Social Benefits from Reduced Alcohol Consumption: When Less is More", hosted by MEP Jonas Sjöstedt. Organised by IOGT-NTO, in collaboration with EBC [...]

28 02-2025

2024 WHO European Health Report

2025-03-04T14:34:09+00:0028-02-2025|News|

On 24 February 2025, the World Health Organization (WHO) released its 2024 European Health Report, marking the end of the European Programme of Work 2020-2025 and reflecting on key achievements and major public health challenges the European region is facing. It is structured into several sections, covering topics such as non-communicable diseases and mental [...]

28 02-2025

Rare Disease Day 2025

2025-03-19T09:27:19+00:0028-02-2025|Uncategorized|

Towards A Rare Brain Disease Ecosystem Rare Disease Day 2025 | 'More than you can imagine' The Rare Disease Day event 2025, organised by the European Brain Council (EBC), was held on February 20, 2025. The event gathered researchers, clinicians, policymakers, industry representatives and patient advocacy groups to address [...]

Go to Top